$470 Million is the total value of Ghost Tree Capital, LLC's 55 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 140.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XBI | Buy | SPDR SERIES TRUSTput | $47,935,000 | +9030.5% | 500,000 | +9900.0% | 10.19% | +6473.5% |
| SRPT | Buy | SAREPTA THERAPEUTICS INC | $33,917,000 | +46.6% | 210,000 | +20.0% | 7.21% | +5.9% |
| ECYT | Buy | ENDOCYTE INC | $19,536,000 | +183.1% | 1,100,000 | +120.0% | 4.15% | +104.4% |
| TSRO | New | TESARO INC | $17,555,000 | – | 450,000 | +100.0% | 3.73% | – |
| DRNA | Buy | DICERNA PHARMACEUTICALS INC | $16,786,000 | +107.6% | 1,100,000 | +66.7% | 3.57% | +50.0% |
| ASND | Buy | ASCENDIS PHARMA A Ssponsored adr | $15,944,000 | +37.0% | 225,000 | +28.6% | 3.39% | -1.1% |
| MRTX | New | MIRATI THERAPEUTICS INCput | $14,130,000 | – | 300,000 | +100.0% | 3.00% | – |
| FXF | New | INVESCO CURNCYSHS SWISS FRANswiss franc | $12,266,000 | – | 128,700 | +100.0% | 2.61% | – |
| ASMB | Buy | ASSEMBLY BIOSCIENCES INC | $12,071,000 | +31.0% | 325,000 | +38.3% | 2.57% | -5.4% |
| ACAD | New | ACADIA PHARMACEUTICALS INCcall | $10,380,000 | – | 500,000 | +100.0% | 2.21% | – |
| RTRX | New | RETROPHIN INC | $10,056,000 | – | 350,000 | +100.0% | 2.14% | – |
| ZGNX | New | ZOGENIX INC | $9,920,000 | – | 200,000 | +100.0% | 2.11% | – |
| RCKT | Buy | ROCKET PHARMACEUTICALS INC | $9,848,000 | +43.3% | 400,000 | +14.3% | 2.09% | +3.5% |
| OBSV | Buy | OBSEVA SA | $9,646,000 | +59.3% | 535,000 | +33.8% | 2.05% | +15.0% |
| ZFGN | Buy | ZAFGEN INC | $8,768,000 | +738.2% | 750,000 | +633.4% | 1.86% | +505.2% |
| PTLA | New | PORTOLA PHARMACEUTICALS INC | $7,989,000 | – | 300,000 | +100.0% | 1.70% | – |
| TCDA | Buy | TRICIDA INC | $7,638,000 | +37.3% | 250,000 | +34.4% | 1.62% | -0.8% |
| BHVN | New | BIOHAVEN PHARMACTL HLDG CO L | $7,510,000 | – | 200,000 | +100.0% | 1.60% | – |
| KDMN | Buy | KADMON HLDGS INC | $6,680,000 | -11.9% | 2,000,000 | +5.3% | 1.42% | -36.4% |
| ANAB | Buy | ANAPTYSBIO INC | $5,986,000 | +436.9% | 60,000 | +282.2% | 1.27% | +287.8% |
| GBT | New | GLOBAL BLOOD THERAPEUTICS INcall | $5,700,000 | – | 150,000 | +100.0% | 1.21% | – |
| KALV | New | KALVISTA PHARMACEUTICALS INC | $4,975,000 | – | 225,000 | +100.0% | 1.06% | – |
| ALNY | New | ALNYLAM PHARMACEUTICALS INCcall | $4,376,000 | – | 50,000 | +100.0% | 0.93% | – |
| BDSI | Buy | BIODELIVERY SCIENCES INTL IN | $4,200,000 | +0.9% | 1,500,000 | +6.3% | 0.89% | -27.1% |
| BCRX | New | BIOCRYST PHARMACEUTICALS | $3,815,000 | – | 500,000 | +100.0% | 0.81% | – |
| UROV | New | UROVANT SCIENCES LTD | $3,600,000 | – | 300,000 | +100.0% | 0.76% | – |
| RDUS | New | RADIUS HEALTH INC | $3,560,000 | – | 200,000 | +100.0% | 0.76% | – |
| ALLK | New | ALLAKOS INC | $3,374,000 | – | 75,000 | +100.0% | 0.72% | – |
| ARVN | New | ARVINAS INC | $2,952,000 | – | 175,000 | +100.0% | 0.63% | – |
| AQXP | New | AQUINOX PHARMACEUTICALS INC | $1,465,000 | – | 500,000 | +100.0% | 0.31% | – |
| SAGE | New | SAGE THERAPEUTICS INC | $1,342,000 | – | 9,500 | +100.0% | 0.28% | – |
| FATE | New | FATE THERAPEUTICS INC | $1,222,000 | – | 75,000 | +100.0% | 0.26% | – |
| GRTS | New | GRITSTONE ONCOLOGY INC | $1,068,000 | – | 75,000 | +100.0% | 0.23% | – |
| EDGE | Buy | EDGE THERAPEUTICS INC | $820,000 | +6.1% | 1,000,000 | +33.2% | 0.17% | -23.3% |
| SPPI | Buy | SPECTRUM PHARMACEUTICALS INC | $793,000 | +30.4% | 47,200 | +62.8% | 0.17% | -5.6% |
| INSM | New | INSMED INC | $526,000 | – | 26,000 | +100.0% | 0.11% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2020-04-09
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MIRATI THERAPEUTICS INC | 30 | Q3 2023 | 7.3% |
| ASCENDIS PHARMA A/S - ADR | 28 | Q3 2023 | 11.8% |
| BIOCRYST PHARMACEUTICALS INC | 25 | Q2 2023 | 2.4% |
| AMICUS THERAPEUTICS INC | 23 | Q3 2023 | 5.6% |
| SAREPTA THERAPEUTICS INC | 22 | Q3 2023 | 9.1% |
| SPDR SER TR | 20 | Q3 2022 | 16.9% |
| IOVANCE BIOTHERAPEUTICS INC | 18 | Q2 2023 | 5.5% |
| ROCKET PHARMACEUTICALS INC | 18 | Q2 2023 | 6.1% |
| SAGE THERAPEUTICS INC | 18 | Q1 2021 | 4.8% |
| IMMUNOMEDICS INC | 17 | Q2 2020 | 8.7% |
View Ghost Tree Capital, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-16 |
View Ghost Tree Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.